BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 9462740)

  • 21. Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia.
    Grimwade D; Solomon E
    Curr Top Microbiol Immunol; 1997; 220():81-112. PubMed ID: 9103677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
    Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
    Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies.
    Koken MH; Reid A; Quignon F; Chelbi-Alix MK; Davies JM; Kabarowski JH; Zhu J; Dong S; Chen S; Chen Z; Tan CC; Licht J; Waxman S; de Thé H; Zelent A
    Proc Natl Acad Sci U S A; 1997 Sep; 94(19):10255-60. PubMed ID: 9294197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia.
    So CW; Dong S; So CK; Cheng GX; Huang QH; Chen SJ; Chan LC
    Leukemia; 2000 Jan; 14(1):77-83. PubMed ID: 10637480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
    He LZ; Tolentino T; Grayson P; Zhong S; Warrell RP; Rifkind RA; Marks PA; Richon VM; Pandolfi PP
    J Clin Invest; 2001 Nov; 108(9):1321-30. PubMed ID: 11696577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling.
    Ruthardt M; Testa U; Nervi C; Ferrucci PF; Grignani F; Puccetti E; Grignani F; Peschle C; Pelicci PG
    Mol Cell Biol; 1997 Aug; 17(8):4859-69. PubMed ID: 9234742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptional regulation in acute promyelocytic leukemia.
    Lin RJ; Sternsdorf T; Tini M; Evans RM
    Oncogene; 2001 Oct; 20(49):7204-15. PubMed ID: 11704848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.
    Gu BW; Xiong H; Zhou Y; Chen B; Wang L; Dong S; Yu ZY; Lu LF; Zhong M; Yin HF; Zhu GF; Huang W; Ren SX; Gallagher RE; Waxman S; Chen GQ; Wang ZG; Chen Z; Fu G; Chen SJ
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7640-5. PubMed ID: 12032336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF.
    Dhordain P; Albagli O; Honore N; Guidez F; Lantoine D; Schmid M; The HD; Zelent A; Koken MH
    Oncogene; 2000 Dec; 19(54):6240-50. PubMed ID: 11175338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
    Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H
    J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The molecular biology of acute promyelocytic leukemia.
    Slack JL; Gallagher RE
    Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
    Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia.
    Matsushita H; Scaglioni PP; Bhaumik M; Rego EM; Cai LF; Majid SM; Miyachi H; Kakizuka A; Miller WH; Pandolfi PP
    J Exp Med; 2006 Apr; 203(4):821-8. PubMed ID: 16549595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia.
    Côté S; Zhou D; Bianchini A; Nervi C; Gallagher RE; Miller WH
    Blood; 2000 Nov; 96(9):3200-8. PubMed ID: 11050004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
    Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
    Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcription therapy for acute promyelocytic leukaemia.
    Douer D
    Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications.
    He LZ; Merghoub T; Pandolfi PP
    Oncogene; 1999 Sep; 18(38):5278-92. PubMed ID: 10498880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.
    Testa U; Grignani F; Samoggia P; Zanetti C; Riccioni R; Lo Coco F; Diverio D; Felli N; Passerini CG; Grell M; Pelicci PG; Peschle C
    J Clin Invest; 1998 May; 101(10):2278-89. PubMed ID: 9593784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia.
    Guidez F; Parks S; Wong H; Jovanovic JV; Mays A; Gilkes AF; Mills KI; Guillemin MC; Hobbs RM; Pandolfi PP; de Thé H; Solomon E; Grimwade D
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18694-9. PubMed ID: 18000064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
    Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
    Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.